Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Abcellera Biologics Inc (ABCL)

Abcellera Biologics Inc (ABCL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,200,333
  • Shares Outstanding, K 299,335
  • Annual Sales, $ 28,830 K
  • Annual Income, $ -162,860 K
  • EBIT $ -233 M
  • EBITDA $ -136 M
  • 60-Month Beta 0.70
  • Price/Sales 41.84
  • Price/Cash Flow N/A
  • Price/Book 1.25

Options Overview Details

View History
  • Implied Volatility 125.14% ( +25.25%)
  • Historical Volatility 73.35%
  • IV Percentile 88%
  • IV Rank 20.73%
  • IV High 352.21% on 04/08/25
  • IV Low 65.76% on 01/21/25
  • Put/Call Vol Ratio 6.17
  • Today's Volume 588
  • Volume Avg (30-Day) 3,698
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 118,915
  • Open Int (30-Day) 102,316

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.17
  • Number of Estimates 4
  • High Estimate -0.14
  • Low Estimate -0.21
  • Prior Year -0.11
  • Growth Rate Est. (year over year) -54.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.42 +16.81%
on 11/07/25
6.23 -35.86%
on 10/15/25
-1.54 (-27.76%)
since 10/10/25
3-Month
3.42 +16.81%
on 11/07/25
6.51 -38.68%
on 10/08/25
-0.28 (-6.44%)
since 08/12/25
52-Week
1.89 +111.38%
on 04/07/25
6.51 -38.68%
on 10/08/25
+1.03 (+34.97%)
since 11/12/24

Most Recent Stories

More News
AbCellera Appoints Dr. Stephen Quake to its Board of Directors

AbCellera (Nasdaq: ABCL) today announced the appointment of Stephen Quake, D.Phil., to its Board of Directors as an independent director. Dr. Quake is a distinguished scientist, inventor,...

ABCL : 3.97 (-1.00%)
AbCellera Reports Q3 2025 Business Results

AbCellera (Nasdaq: ABCL) today announced financial results for the third quarter of 2025. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. ...

ABCL : 3.97 (-1.00%)
AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

AbCellera (Nasdaq: ABCL) today announced that the Company will participate in the following investor conferences: Truist Securities BioPharma Symposium, November 6,...

ABCL : 3.97 (-1.00%)
AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

AbCellera (Nasdaq: ABCL) will announce its third quarter 2025 financial results on Thursday, November 6, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern...

ABCL : 3.97 (-1.00%)
AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

AbCellera (Nasdaq: ABCL) today announced the appointment of Sarah Noonberg, M.D., Ph.D., as Chief Medical Officer. Dr. Noonberg, a board-certified physician-scientist, brings over two decades of...

ABCL : 3.97 (-1.00%)
I Asked ChatGPT’s Most Advanced Model to Find the Stocks Most Likely to 100x Over the Next 10 Years — Here’s What It Said

Here are the stocks that ChatGPT's most advanced model says are most likely to 100x over the next 10 years.

NVDA : 192.20 (-0.50%)
SLDP : 6.49 (-8.59%)
AI : 14.85 (-3.00%)
RKLB : 50.52 (-1.41%)
RXRX : 4.61 (-2.12%)
IONQ : 52.18 (-4.12%)
NNDM : 1.5501 (-1.27%)
ASTS : 64.91 (-4.39%)
ORGN : 0.5300 (unch)
ARQQ : 30.42 (-3.15%)
AEHR : 22.95 (-0.91%)
ABCL : 3.97 (-1.00%)
AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

ABCL575 is an Fc-silenced, half-life extended investigational antibody therapy that is being developed for the treatment of atopic dermatitis

ABCL : 3.97 (-1.00%)
AbCellera to Participate at Upcoming Investor Conferences in September

AbCellera (Nasdaq: ABCL) today announced that the Company will participate in the following investor conferences: Wells Fargo Healthcare Conference, September 3-5,...

ABCL : 3.97 (-1.00%)
AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

AbCellera (Nasdaq: ABCL) today announced financial results for the second quarter of 2025 and that dosing has begun in a Phase 1 clinical trial of ABCL635 for the potential treatment of moderate-to-severe...

ABCL : 3.97 (-1.00%)
Why AbCellera Biologics Stock Raced Nearly 6% Higher Today

ABCL : 3.97 (-1.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635 and ABCL575. AbCellera Biologics Inc. is based in Vancouver, Canada.

See More

Key Turning Points

3rd Resistance Point 4.32
2nd Resistance Point 4.17
1st Resistance Point 4.09
Last Price 3.97
1st Support Level 3.86
2nd Support Level 3.71
3rd Support Level 3.63

See More

52-Week High 6.51
Fibonacci 61.8% 4.75
Fibonacci 50% 4.20
Last Price 3.97
Fibonacci 38.2% 3.66
52-Week Low 1.89

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar